NSCLC EA5163
Study #EA5163INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone of in Combination with Chemotherapy in Induction / Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunoblocker SIGNature-Driven Analysis
Back To Clinical Trials NCI Database Entry